Sugi Predict

Sugi Predict / Targets / PTH1R

PTH1R

Parathyroid hormone/parathyroid hormone-related peptide receptor · Q03431 · PTH1R on Sugi Atlas →

7,637 patent compounds predicted against PTH1R, 4,279 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL847426 SCHEMBL847426 0.74 15/20
Teriparatide Teriparatide (SCHEMBL720581) 0.90 14/20
SCHEMBL847260 SCHEMBL847260 0.70 13/20
SCHEMBL849189 SCHEMBL849189 1.00 12/20
SCHEMBL849343 SCHEMBL849343 1.00 12/20
SCHEMBL847518 SCHEMBL847518 0.91 12/20
SCHEMBL848732 SCHEMBL848732 0.87 12/20
SCHEMBL849103 SCHEMBL849103 0.86 12/20
SCHEMBL849104 SCHEMBL849104 0.86 12/20
SCHEMBL849168 SCHEMBL849168 0.86 12/20
SCHEMBL848289 SCHEMBL848289 0.85 12/20
SCHEMBL848810 SCHEMBL848810 0.85 12/20
SCHEMBL849538 SCHEMBL849538 0.85 12/20
SCHEMBL849539 SCHEMBL849539 0.85 12/20
SCHEMBL849421 SCHEMBL849421 0.84 12/20
SCHEMBL849328 SCHEMBL849328 0.84 12/20
SCHEMBL849529 SCHEMBL849529 0.84 12/20
SCHEMBL847673 SCHEMBL847673 0.83 12/20
SCHEMBL848709 SCHEMBL848709 0.83 12/20
SCHEMBL848710 SCHEMBL848710 0.83 12/20

Clinical trials — most relevant to PTH1R by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid PHASE4COMPLETED
Vitamin D Repletion in Primary Hyperparathyroidism PHASE4COMPLETED
Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate PHASE4COMPLETED
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis PHASE3COMPLETED
Calcium Supplementation in Postmenopausal Women PHASE3COMPLETED
PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism PHASE3COMPLETED
HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism PHASE3COMPLETED
Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1) PHASE2/PHASE3RECRUITING
Treatment With PTH After Sternotomy in Cardiac Surgery Patients PHASE3COMPLETED
Comparison Study of PTHrP and PTH to Treat Osteoporosis PHASE2COMPLETED
The Effect of Etelcalcetide on CKD-MBD PHASE2COMPLETED
PTHrP(1-36) IV Dose Escalation Study PHASE1WITHDRAWN
One Week Comparison Study of PTH and PTHrP Infusions PHASE1WITHDRAWN
Corticosteroid Rhythms in Hypoparathyroid Patients EARLY_PHASE1UNKNOWN
Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism nanUNKNOWN
Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome nanUNKNOWN
OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism nanCOMPLETED
Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption nanCOMPLETED
Evaluation of Microbial and Endocrinological Parameters in Dialysis Patients With Sepsis nanRECRUITING
Utility of a Urine Screening Tool for Vitamin D Deficiency in Infants and Toddlers nanCOMPLETED
Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation nanCOMPLETED
Gait and Balance Parameters Before and After Parathyroidectomy in Patients With Primary Hyperparathyroidism nanCOMPLETED
QoL and Cognitive Function in Patients With Hypoparathyroidism nanCOMPLETED
Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior nanCOMPLETED
The Bone-parathyroid Crosstalk in Primary Hyperparathyroidism nanUNKNOWN
The Role Of FGF23, Klotho, And Sclerostin In Kidney Stone Formers nanUNKNOWN
Translation and Validation of the Hypoparathyroidism Patient Experience Scales (HPES) Questionnaire in Greek nanNOT_YET_RECRUITING
Palopegteriparatide in Chronic Hypoparathyroidism nanCOMPLETED
Physiologic Regulation of FGF-23 nanCOMPLETED
18F-choline Positron-emission-tomography - Computed-tomography Compared to Conventional Imaging for Localizing Diseased Parathyroid Glands in Primary Hyperparathyroidism nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PTH1R binder may also engage these)

ProteinNameSimilarity
P25961 — 1.000 P25961 →
Q5RAQ1 — 1.000 Q5RAQ1 →
Q1LZF7 — 1.000 Q1LZF7 →
P50133 — 0.999 P50133 →
Q9TU31 — 0.998 Q9TU31 →
P41593 — 0.995 P41593 →
P25107 — 0.993 P25107 →
GLP1R Glucagon-like peptide 1 receptor 0.992 landscape →
P49190 — 0.989 P49190 →
Q02644 — 0.989 Q02644 →
O95838 — 0.988 O95838 →
VIPR2 Vasoactive intestinal polypeptide receptor 2 0.988 landscape →
Q60755 — 0.987 Q60755 →
Q63118 — 0.985 Q63118 →
O35659 — 0.985 O35659 →
Q9W4Y2 — 0.985 Q9W4Y2 →
Q61606 — 0.985 Q61606 →
P25117 — 0.985 P25117 →
GCGR Glucagon receptor 0.984 landscape →
P91682 — 0.984 P91682 →
Q91V95 — 0.984 Q91V95 →
B4HS00 — 0.984 B4HS00 →
Q9Z0W0 — 0.984 Q9Z0W0 →
P20792 — 0.984 P20792 →
CALCR Calcitonin receptor 0.983 landscape →
Q5FWI2 — 0.983 Q5FWI2 →
P32214 — 0.983 P32214 →
B2RXE2 — 0.983 B2RXE2 →
P30082 — 0.983 P30082 →
P70555 — 0.983 P70555 →